CoChat
Sign Up
Cited by 14Schizophrenia research and treatmentGenomic variations and chromosomal abnormalitiesWilliams Syndrome Research

The interaction between neurocognitive functioning, subthreshold psychotic symptoms and pharmacotherapy in 22q11.2 deletion syndrome: A longitudinal comparative study

Open access
Weinberger, R., Weisman, O., Guri, Y., Harel, T., Weizman, A., Gothelf, D.·2018·European Psychiatry
DOI 10.1016/j.eurpsy.2017.10.010
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: The 22q11.2 deletion syndrome (22q11DS) is the most common genetic syndrome associated with schizophrenia. The goal of this study was to evaluate longitudinally the interaction between neurocognitive functioning, the presence of subthreshold psychotic symptoms (SPS) and conversion to psychosis in individuals with 22q11DS. In addition, we attempted to identify the specific neurocognitive domains that predict the longitudinal evolution of positive and negative SPS, as well as the effect of psychiatric medications on 22q11DS psychiatric and cognitive developmental trajectories. Methods: Forty-four participants with 22q11DS, 19 with Williams syndrome (WS) and 30 typically developing (TD) controls, age range 12–35 years, were assessed at two time points (15.2 ± 2.1 months apart). Evaluation included the Structured Interview for Prodromal Symptoms (SIPS), structured psychiatric evaluation and the Penn Computerized Neurocognitive Battery (CNB). Results: 22q11DS individuals with SPS had a yearly conversion rate to psychotic disorders of 8.8%, compared to none in both WS and TD controls. Baseline levels of negative SPS were associated with global neurocognitive performance (GNP), executive function and social cognition deficits, in individuals with 22q11DS, but not in WS. Deficits in GNP predicted negative SPS in 22q11DS and the emergence or persistence of negative SPS. 22q11DS individuals treated with psychiatric medications showed significant improvement in GNP score between baseline and follow-up assessments, an improvement that was not seen in untreated 22q11DS. Conclusions: Our results highlight the time-dependent interplay among positive and negative SPS symptoms, neurocognition and pharmacotherapy in the prediction of the evolution of psychosis in 22q11DS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eurpsy.2017.10.010

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 33

  1. McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JA, et al. 22q11: 2 deletion syndrome. Nat Rev Dis Prim 2015;1:15071.
  2. Schneider M, Debbane M, Bassett AS, Chow EW, Fung WL, van den Bree M, et al. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Am J Psychiatry 2014;171:627-39.
  3. Gothelf D, Feinstein C, Thompson T, Gu E, Penniman L, Van Stone E, et al. Risk factors for the emergence of psychotic disorders in adolescents with 22q11: 2 deletion syndrome. Am J Psychiatry 2007;164:663-9.
  4. Vorstman JA, Breetvelt EJ, Duijff SN, Eliez S, Schneider M, Jalbrzikowski M, et al. Cognitive decline preceding the onset of psychosis in patients with 22q11. 2 deletion syndrome. JAMA Psychiatry 2015;72:377-85.
  5. Antshel KM, Shprintzen R, Fremont W, Higgins AM, Faraone SV, Kates WR. Cognitive and psychiatric predictors to psychosis in velocardiofacial syndrome: a 3-year follow-up study. J Am Acad Child Adolesc Psychiatry 2010;49:333-44.
  6. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull 2010;36:359-69.
  7. Piskulic D, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, et al. Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res 2012;196:220-4.
  8. Basso MR, Nasrallah HA, Olson SC, Bornstein RA. Neuropsychological correlates of negative, disorganized and psychotic symptoms in schizophrenia. Schizophr Res 1998;31:99-111.
  9. Lincoln TM, Mehl S, Kesting M-L, Rief W. Negative symptoms and social cognition: identifying targets for psychological interventions. Schizophr Bull 2011;37:S23-32.
  10. Tang SX, Yi JJ, Moore TM, Calkins ME, Kohler CG, Whinna DA, et al. Subthreshold psychotic symptoms in 22q11.2 deletion syndrome. J Am Acad Child Adolesc Psychiatry 2014;53:991-1000 e2.
  11. Schneider M, Van der Linden M, Menghetti S, Glaser B, Debbané M, Eliez S. Predominant negative symptoms in 22q11: 2 deletion syndrome and their associations with cognitive functioning and functional outcome. J Psychiatr Res 2014;48:86-93.
  12. Schneider M, Eliez S, Birr J, Menghetti S, Debbané M, Van der Linden M. Multitasking abilities in adolescents with 22q11. 2 deletion syndrome: results from an experimental ecological paradigm. Am J Intell Dev Disabil 2016;121:151-64.
  13. Maeder J, Schneider M, Bostelmann M, Debbané M, Glaser B, Menghetti S, et al. Developmental trajectories of executive functions in 22q11: 2 deletion syndrome. J. Neurodev Disord 2016;8:10.
  14. Kates W, Russo N, Wood W, Antshel K, Faraone S, Fremont W. Neurocognitive and familial moderators of psychiatric risk in velocardiofacial (22q11. 2 deletion) syndrome: a longitudinal study. Psychol Med 2015;45:1629-39.
  15. Zarchi O, Diamond A, Weinberger R, Abbott D, Carmel M, Frisch A, et al. A comparative study of the neuropsychiatric and neurocognitive phenotype in two microdeletion syndromes: velocardiofacial (22q11.2 deletion) and Williams (7q11.23 deletion) syndromes. Eur Psychiatry 2014;29:203-10.
  16. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003;29: 703.
  17. McGlashan T, Walsh B, Woods S. The psychosis-risk syndrome: handbook for diagnosis and follow-up. Oxford University Press; 2010.
  18. Dominguez MD, Wichers M, Lieb R, Wittchen HU, van Os J. Evidence that onset of clinical psychosis is an outcome of progressively more persistent subclinical psychotic experiences: an 8-year cohort study. Schizophr Bull 2011;37:84-93.
  19. Tang S, Moore T, Calkins M, Yi J, McDonald-McGinn D, Zackai E, et al. Emergent, remitted and persistent psychosis-spectrum symptoms in 22q11: 2 deletion syndrome. Transl Psychiatry 2017;7:e1180.
  20. Gothelf D, Schneider M, Green T, Debbane M, Frisch A, Glaser B, et al. Risk factors and the evolution of psychosis in 22q11.2 deletion syndrome: a longitudinal 2-site study. J Am Acad Child Adolesc Psychiatry 2013;52:1192- 203 e3.
  21. Gothelf D, Feinstein C, Thompson T, Gu E, Penniman L, Van Stone E, et al. Risk factors for the emergence of psychotic disorders in adolescents with 22q11: 2 deletion syndrome. Am J Psychiatry 2007;164:663-9.
  22. Tang SX, Moore TM, Calkins ME, Yi JJ, McDonald-McGinn DM, Zackai EH, et al. Emergent, remitted and persistent psychosis-spectrum symptoms in 22q11.2 deletion syndrome. Transl Psychiatry 2017;7:e1180.
  23. Addington J, Liu L, Buchy L, Cadenhead KS, Cannon TD, Cornblatt BA, et al. North American Prodrome Longitudinal Study (NAPLS 2): The Prodromal Symptoms. J Nerv Mental Dis 2015;203:328-35.
  24. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Probably at-risk, but certainly ill-advocating the introduction of a psychosis spectrum disorder in DSM-V. Schizophr Res 2010;120:23-37.
  25. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, et al. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012;69:220-9.
  26. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze- Lutter F, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2012;70:1-14.
  27. Carrion RE, McLaughlin D, Auther AM, Olsen R, Correll CU, Cornblatt BA. The impact of psychosis on the course of cognition: a prospective, nested case- control study in individuals at clinical high-risk for psychosis. Psychol Med 2015;45:3341-54.
  28. Gur RC, Calkins ME, Satterthwaite TD, Ruparel K, Bilker WB, Moore TM, et al. Neurocognitive growth charting in psychosis spectrum youths. JAMA Psychiatry 2014;71:366-74.
  29. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, et al. Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. Arch Gen Psychiatry 2010;67:578-88.
  30. Kates WR, Olszewski AK, Gnirke MH, Kikinis Z, Nelson J, Antshel KM, et al. White matter microstructural abnormalities of the cingulum bundle in youths with 22q11 2 deletion syndrome: associations with medication, neuropsychological function, and prodromal symptoms of psychosis. Schizophr Res 2015;161:76-84.
  31. Green T, Weinberger R, Diamond A, Berant M, Hirschfeld L, Frisch A, et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. J Child Adolesc Psychopharmacol 2011;21:589-95.
  32. Schneider M, Van der Linden M, Menghetti S, Glaser B, Debbane M, Eliez S. Predominant negative symptoms in 22q11: 2 deletion syndrome and their associations with cognitive functioning and functional outcome. J Psychiatr Res 2014;48:86-93.
  33. Jalbrzikowski M, Carter C, Senturk D, Chow C, Hopkins JM, Green MF, et al. Social cognition in 22q11.2 microdeletion syndrome: relevance to psychosis? Schizophr Res 2012;142:99-107.

Cited by

Sorted by citations

Authors
Weinberger, R., Weisman, O., Guri, Y., Harel, T., Weizman, A., & Gothelf, D.
Affiliations
  • Tel Aviv University (IL)
  • Sheba Medical Center (IL)
Corresponding author
Gothelf, D.
ORCID
Venue
European Psychiatry
Publisher
Cambridge University Press (CUP)
Published
2018
Volume
48
Issue
1
Pages
20-26
ISSN
  • 0924-9338 (ISSN-L)
  • 1778-3585
DOI
10.1016/j.eurpsy.2017.10.010
OpenAlex
W2784306974
Cited by
14
References
1
Citations by year
2026: 3 · 2024: 1 · 2023: 3 · 2021: 5 · 2019: 1 · 2018: 1
FWCI
1.38
Type
journal article
Language
en
Open access
Licence
Locations
  • European Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Mental Health (U01MH101722)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
  • Life Sciences › Neuroscience › Developmental Neuroscience › Williams Syndrome Research
Keywords
22q11.2 deletion syndrome, Williams syndrome, subthreshold psychotic symptoms, prodromal psychosis, transition to psychosis, neurocognitive function, executive function, social cognition, negative psychotic symptoms, positive psychotic symptoms, antipsychotic pharmacotherapy, schizophrenia risk, cognitive development
MeSH terms
Adolescent, Adult, Child, Cognition, DiGeorge Syndrome, Female, Humans, Longitudinal Studies, Male, Psychotic Disorders, Schizophrenia, Social Behavior, Antipsychotic Agents, Williams Syndrome, Young Adult, Executive Function, Prodromal Symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review